• Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago

  • Nov 30 2022
  • Length: 9 mins
  • Podcast
Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago By cover art

Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago

Listen for free

View show details

  • Summary

  • Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout

    Find out more at
    https://LifeScienceTodayPodcast.com

    Story References
    Sanofi/Takeda
    UniQure & CSL
    Fog Pharma
    Merck + Imago

    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 
    Show more Show less
Show more Show less

What listeners say about Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available